PRESS RELEASE

Janssen Diagnostics and Biocartis announce launch of Influenza-Respiratory Virus Panel on the Idylla™ platform

Mechelen and Beerse, Belgium, 30 November 2015 - Janssen Diagnostics, part of the Johnson & Johnson family of companies (NYSE: JNJ) and Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announced the launch of their first infectious disease test on the Idylla™ platform. The Idylla™ Respiratory IFV-RSV Panel has been developed by Janssen Diagnostics and is intended for the detection of various strains of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV). The Idylla™ Respiratory IFV-RSV Panel received CE-IVD marking on 18 November 2015 and is being launched for commercial use in Europe and other geographies recognising the CE-mark. Janssen Diagnostics has appointed Biocartis as co-exclusive worldwide distributor of the test.

Respiratory viruses are one of the most important causes of morbidity and mortality throughout the world[1] with the influenza virus killing at least 50 million and up to 100 million people in the last century alone[2]. The majority of diagnostic tests currently used for this market are rapid immunoassays which are chosen due to their low cost and convenience. However, one of the key downsides of these rapid tests is their poor sensitivity. Negative samples are typically re-tested in a central lab with a more sensitive molecular test, delaying time-to-result by many hours. The new Idylla™ Respiratory IFV-RSV Panel, running on the Idylla™ platform, combines in one single product the speed of rapid tests with the quality and sensitivity standards of central lab tests.

The Idylla™ Respiratory IFV-RSV Panel is designed for the qualitative detection of nucleic acids of Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype 2009 H1, H275Y mutation of Influenza A subtype 2009 H1, Influenza B and Respiratory Syncytial Virus (RSV) subtype A and RSV subtype B from nasopharyngeal swabs (NPS[3]) of adult and pediatric patients, using the Idylla™ molecular diagnostic platform to aid in the diagnosis of respiratory viral infection.

Thanks to the fully integrated workflow and outstanding ease-of-use of the Idylla™ platform, the Idylla™ Respiratory IFV-RSV Panel can be performed in as little as 50 minutes and requires less than one minute of hands-on time.

After Biocartis launched its solid biopsy BRAF Mutation Test for melanoma and solid biopsy KRAS Mutation Test for colorectal cancer, this Idylla™ Respiratory IFV-RSV Panel is the first of a series of infectious disease tests that Biocartis and its partners are developing for use on the Idylla™ platform.

Rudi Pauwels, CEO Biocartis, states: "*Collaboration is a key aspect of the strategy that we outlined at the time of our Initial Public Offering, in order to accelerate our menu development and speed up our commercial reach. Janssen has been a long-standing and very supportive partner of Biocartis. We are therefore delighted with the launch of such a high performance quality Idylla™ Respiratory IFV-RSV Panel. The combination of oncology and infectious disease tests demonstrates the versatility of our Idylla™ platform, one of the reasons why Janssen Diagnostics chose to work with Biocartis.*"

[1] WHO: The global burden of disease: 2004 update. WHO Press, Geneva, Switzerland.
[2] "The Threat of Pandemic Influenza: Are We Ready?"; http://www.ncbi.nlm.nih.gov/books/NBK22148/
[3] The test is compatible with both dry NPS swabs as well as with a viral transport medium.

Werner Verbiest, Global Head of Janssen Diagnostics, adds: "*Janssen and Biocartis share the ambition to develop high precision diagnostic solutions to enable high precision medicine. With our promising pipeline of Respiratory Syncytial Virus and Influenza antiviral therapies, we feel it is important for our patients to have access to reliable and state-of-the-art solutions for rapid molecular testing. Thanks to its cutting edge technology, the Biocartis Idylla™ platform has the potential to perform complex and robust testing, such as our very sensitive Idylla™ Respiratory IFV-RSV Panel, outside of the central laboratory setting. This enables a whole new way of complex diagnostic testing, performed closer to the patient.*"

Biocartis is planning to roll-out a range of infectious disease tests in the coming years. The Idylla™ Rapid Ebola Virus Triage Test, developed in association with Janssen Diagnostics and the Institute for Tropical Medicine in Antwerp (Belgium), is expected to be the next infectious disease test on Idylla™. Biocartis and Janssen are committed to making a difference with high precision diagnostics and more effective treatments to face unmet needs in infectious diseases.

----- END ----

For more information:

Biocartis
Renate Degrave (Corporate Communications & Investor Relations)
+32 15 632 600 | press@biocartis.com

Consilium Strategic Communications
Amber Fennell, Jessica Hodgson, Chris Welsh, Hendrik Thys
+44 (0) 203 709 5701 (London, UK) | biocartis@consilium-comms.com

The Janssen Pharmaceutical Companies of Johnson & Johnson
Frederik Wittock (R&D Communications)
+32-14-60-57-24 | fwittock@its.jnj.com

About Janssen Diagnostics

Janssen Diagnostics is committed to saving and improving patients' lives through the integration and delivery of differentiating diagnostic and health IT solutions into world-class personalized disease management. Building beyond our joint legacy of world-class diagnostic interventions, our mission is to invest and partner in driving revolutionary diagnostic solutions in oncology, infectious diseases, central nervous system diseases, immunologic and cardiovascular disease.

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis launched the Idylla™ platform commercially in September 2014 together with its first assay to identify BRAF Mutations in metastatic melanoma. Its second assay, a KRAS Mutation panel for colorectal cancer, was launched in June 2015. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Further information can be found at: www.biocartis.com.